Aug 07, 2019
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
Jul 23, 2019
Theranica: New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications
Jul 11, 2019
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache
Jul 09, 2019
Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting
Jul 01, 2019
New Trial Shows Cefaly is a Safe and Effective Preventive Treatment for Chronic Migraine
Jun 25, 2019
Global Leaders in Migraine Research to Convene at The American Headache Society 61st Annual Scientific Meeting
Jun 04, 2019
FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks
May 14, 2019
Biotech Stocks: Latest Technological Developments Pushing U.S. Medical Device Market to New Levels
May 08, 2019
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
May 06, 2019
AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups
Apr 04, 2019
Migraine Drugs Market to Touch US$3.72 Billion by 2025, Says TMR
Apr 01, 2019
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
Mar 12, 2019
Terrell Davis, NFL Hall Of Fame Inductee, Reveals His Struggle With Migraine At First-Ever Live Event
Feb 04, 2019
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist
Jan 07, 2019
Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China
Dec 10, 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Dec 04, 2018
Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.
Dec 03, 2018
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Nov 15, 2018
Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine
Nov 02, 2018
Migraine Drugs Market Rising at Steady 3.5% During 2017 - 2025; Abortive Treatment Generates Maximum Revenue - TMR